Search

Coronavirus disease 2019 (COVID‐19) caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐CoV‐2), a pandemic, which has led to the spread of mortality and morbidity all over the globe. In this dire situation, there is an urgent requirement for the development and immediate dissemination of treatment against COVID‐19. The traditional medicine system of Siddha can be utilized as preventive care to boost the immune system. The vast treasure of knowledge found in Siddha medicine can help in the betterment of humankind. Kabasura Kudineer (KSK) is from the ancient times present as an immune-boosting agent against several diseases. The present experimental setup to investigate the immunomodulatory and thrombolytic potential of KSK. The in vitro immunomodulatory models of phagocytosis of Candida albicans assay and nitro blue tetrazolium have demonstrated that KSK is giving better results compared with the controls (pooled serum, lipopolysaccharide, and streptokinase). The KSK at the concentrations of 12.5, 25, 50, and 100 μg/ml showed % immune-stimulations of 12.40 %, 20.81 %, 33.53 %, 43.20 % and for NBT showed 19.00 %, 25.50 %, 64.00 %, 71.00 % respectively. And similarly, the thrombolytic activity showed 50 and 100 μg/ml concentration showed 43.83 %, 71.83 % clot lysis respectively; and the control value for the streptokinase showed 83.78 %. Hence, it can be confirmed that KSK has immunomodulatory and thrombolytic properties in in vitro models, although the in vivo and the identification of KSK are to be discovered.

Siddha Medicine is a valuable therapeutic choice which is classically used for treating viral respiratory infections, this principle of medicine is proven to contain antiviral compounds. In this study, we executed the molecular docking studies for Phytoconstituents of Siddha official formulation Kabasura Kudineer which is used in treating viral fever and respiratory diseases and a Novel Herbal Preparation - JACOM against the ongoing pandemic of novel coronavirus disease causative agent SARS-CoV-2 Spike protein. Further, we also conducted prediction studies on the pharmacokinetics (ADME) properties and the safety profile in order to identify the best drug candidates using pkCSM and SwissADME web servers. Totally 37 compounds were screened, of these 9 compounds showed high binding efficiency. Based on these, we proposed the new formulation called as “SNACK –V”.

In this paper, the existence and uniqueness of common and coincidence fixed points for a pair of self-mappings under generalized rational inequalities are established in complex valued metric spaces with supportive examples. The presented results improve and generalize the existing results in the literature.

Data emerging from the past 10 years have consolidated the rationale for investigating the use of aspirin as a chemopreventive agent; however, the mechanisms leading to its anti-cancer effects are still being elucidated. We hypothesized that aspirin's chemopreventive actions may involve cell cycle regulation through modulation of the levels or activity of cyclin A2/cyclin dependent kinase-2 (CDK2). In this study, HT-29 and other diverse panel of cancer cells were used to demonstrate that both aspirin and its primary metabolite, salicylic acid, decreased cyclin A2 (CCNA2) and CDK2 protein and mRNA levels. The down regulatory effect of either drugs on cyclin A2 levels was prevented by pretreatment with lactacystin, an inhibitor of proteasomes, suggesting the involvement of 26S proteasomes. In-vitro kinase assays showed that lysates from cells treated with salicylic acid had lower levels of CDK2 activity. Importantly, three independent experiments revealed that salicylic acid directly binds to CDK2. Firstly, inclusion of salicylic acid in naïve cell lysates, or in recombinant CDK2 preparations, increased the ability of the anti-CDK2 antibody to immunoprecipitate CDK2, suggesting that salicylic acid may directly bind and alter its conformation. Secondly, in 8-anilino-1-naphthalene-sulfonate (ANS)-CDK2 fluorescence assays, pre-incubation of CDK2 with salicylic acid, dose-dependently quenched the fluorescence due to ANS. Thirdly, computational analysis using molecular docking studies identified Asp145 and Lys33 as the potential sites of salicylic acid interactions with CDK2. These results demonstrate that aspirin and salicylic acid down-regulate cyclin A2/CDK2 proteins in multiple cancer cell lines, suggesting a novel target and mechanism of action in chemoprevention. Citation Format: Rakesh Dachineni, Guoqiang Ai, Ramesh Kumar D, Satya Sadhu, Hemachand Tummala, Jayarama B. Gunaje. Cyclin A2 and CDK2 as Novel Targets of Aspirin and Salicylic acid: a Potential Role in Cancer Prevention. [abstract]. In: Proceedings of the AACR Precision Medicine Series: Cancer Cell Cycle - Tumor Progression and Therapeutic Response; Feb 28-Mar 2, 2016; Orlando, FL. Philadelphia (PA): AACR; Mol Cancer Res 2016;14(11_Suppl):Abstract nr A02.

In this study, the potential of the internet as a medium for training PACS application is incvestigated. Master of Science (Information Studies)